PD-1/L1

Delve into the world of PD-1/L1 in China’s pharmaceutical industry. Fineline Info & Tech provides reliable data, news, and insights on PD-1/L1 to help you navigate complexities with precision and clarity. Stay informed and enhance your decision-making at flcube.com.

Innovent's Sintilimab Plus Nogileucel (GC101) Melanoma NDA Accepted by NMPA – Backed by 57% Progression Risk Reduction in MIZAR-003
Others

Innovent’s Sintilimab Plus Nogileucel (GC101) Melanoma NDA Accepted by NMPA – Backed by 57% Progression Risk Reduction in MIZAR-003

Innovent Biologics, Inc. (HKG: 1801) announced that the marketing application for a new indication of its PD‑1 inhibitor sintilimab (brand name: Tyvyt) has been accepted by China's National Medical Products…

WuXi AppTec Q3 Revenue Jumps 38% as Backlog Hits RMB 76.74 Billion – Full-Year Guidance Raised

WuXi AppTec Q3 Revenue Jumps 38% as Backlog Hits RMB 76.74 Billion – Full-Year Guidance Raised

HutchMed's SANOVO Phase III Hits Primary Endpoint – ORPATHYS Plus TAGRISSO Extends Median PFS to 24.9 Months in MET-Overexpressing EGFR-Mutant NSCLC

HutchMed’s SANOVO Phase III Hits Primary Endpoint – ORPATHYS Plus TAGRISSO Extends Median PFS to 24.9 Months in MET-Overexpressing EGFR-Mutant NSCLC

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Explore Now
CompanyDrug

Ascletis Completes Enrollment for HIV Functional Cure Study with PD-L1 Antibody ASC22

CompanyDrug

Alphamab/3DMed’s Envafolimab Gains FDA Fast-Track Status for Sarcoma Treatment

CompanyDrug

BeiGene’s Tislelizumab Meets Primary Endpoint in HCC Study at ESMO

CompanyDrug

Innovent’s Tyvyt Combo Shows PFS Benefit in EGFR-Mutant NSCLC

CompanyDrug

Innovent’s Tyvyt Shows PFS Benefit in EGFR-Mutant NSCLC at ESMO

CompanyDrug

Alphamab Oncology Highlights KN046, KN026 Advances at ESMO 2022

Company

Henlius Biotech Plans US Bridging Study for Serplulimab in ES-SCLC

CompanyDrug

Akeso Bio’s AK112 Wins Breakthrough Designation for First-Line NSCLC

Show More